{
    "clinical_study": {
        "@rank": "40270", 
        "arm_group": [
            {
                "arm_group_label": "RNS60", 
                "arm_group_type": "Experimental", 
                "description": "RNS60 given intra-articularly as the last 3 liters of irrigation + peripheral i.v. administration."
            }, 
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline given intra-articularly as the last 3 liters of irrigation + peripheral i.v. administration."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if use of RNS60 during hip labral repair surgery\n      decreases pain and improves functional capacity post-operation."
        }, 
        "brief_title": "Study of RNS60 on Pain and Function After Hip Labral Repair", 
        "condition": "Hip Labral Tear", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Medically stable as determined by the Investigator.\n\n          -  Normal 12-lead ECG prior to surgery.\n\n          -  Women of childbearing potential who have a negative pregnancy test (urine HCG) before\n             surgery.\n\n          -  Capable of understanding the purpose and risks of the study and provide written,\n             informed consent.\n\n          -  Patients scheduled to undergo labral repair surgery of the hip.\n\n        Exclusion Criteria:\n\n          -  Morbid obesity.\n\n          -  History of any clinically significant autoimmune disease: inflammatory bowel disease,\n             diabetes, lupus or severe asthma.\n\n          -  Current or prior malignancies (excluding non-melanoma skin carcinoma or in situ\n             carcinoma of the cervix that has been adequately treated).\n\n          -  Significant organ dysfunction, including cardiac, renal (eGFR \u2264 60 ml/min.), liver,\n             central nervous system, pulmonary, vascular, gastrointestinal, endocrine, or\n             metabolic (e.g., creatinine \u2265 1.6 mg/dL; ALT or AST \u2265 1.5x the upper limit of\n             normal), history of myocardial infarction, congestive heart failure, or arrhythmias\n             within 6 months prior to enrollment.\n\n          -  Steroid therapy within 60 days prior to enrollment.\n\n          -  Use of any immunomodulatory drugs during the study.\n\n          -  Participation in any investigational therapy within one year prior to enrollment,\n             unless given approval by PI.\n\n          -  Known or suspected current or past alcohol or drug abuse within one year prior to\n             enrollment.\n\n          -  Any medical, psychiatric or other condition that could result in a subject not being\n             able to comply with protocol requirements.\n\n          -  Evidence of hip dysplasia and/or advanced hip osteoarthritis\n\n          -  Previous trauma or surgery on the relevant hip."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005523", 
            "org_study_id": "07.1.1.H2"
        }, 
        "intervention": [
            {
                "arm_group_label": "RNS60", 
                "intervention_name": "RNS60", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saline", 
                "intervention_name": "Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "contact": {
                "last_name": "Karen Briggs, MPH", 
                "phone": "970-479-5783"
            }, 
            "facility": {
                "address": {
                    "city": "Vail", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "81657"
                }, 
                "name": "Steadman Philippon Research Clinic"
            }, 
            "investigator": {
                "last_name": "Marc Philippon, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of RNS60 on Post-operative Pain and Function in Patients Undergoing Hip Labral Repair or Reconstruction Surgery", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Comparison of scores from validated pain scales from post-surgery to one week.", 
            "measure": "Assessment of post-operative pain", 
            "time_frame": "1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005523"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Revalesio Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Revalesio Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}